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ADCY5-related dyskinesia is a rare movement disorder with early onset in 
childhood and adolescence. Previous studies linked this disease to various point 
mutations in the ADCY5 gene. Recent studies show that two of the point mutations cause 
an increase in cyclic adenosine monophosphate (cAMP) levels. However, it remains 
unknown how increased levels of cAMP result in the phenotypes associated with this 
disease.  My study examines the effects of increased cAMP levels on neuronal 
differentiation of mouse embryonic stem cells (mESCs).  My experiments demonstrated 
successful differentiation of mESCs into the dopaminergic neuronal lineage, indicated by 
the presence of Tuj 1 (a class III beta-tubulin neuronal cell marker), and tyrosine 
hydroxylase (TH) (an enzyme found in dopaminergic neurons), as detected by 
immunocytochemistry (ICC). To determine the effect of cAMP on this process, murine 
embryonic stem cells were differentiated in the presence of a range of db-cAMP 
concentrations. Cells treated with 700 µM of db-cAMP during the differentiation step of 
the protocol showed increased percentage of the neuronal cell-type, followed by a 




There was no significant effect of db-cAMP on percent dopamine-containing neurons.  In 
addition, there were lower levels of tyrosine hydroxylase (TH) protein present in the 
membrane fraction, in cells treated with 1400 µM db-cAMP compared to no treatment, 
and no significant change in cytosolic TH.   My results also revealed an increase in 
dopamine receptor D2 in both the membrane and cytosol.  In order to characterize the 
effects of the point mutation p.R418W on cellular cAMP levels in HEK293T cells,  I 
attempted to create a  mutation in a HEK293T cell line using CRISPR. Once the mutant 
cell line was generated, the plan was to treat with pharmacological agonists to beta-
adrenergic receptors to stimulate cAMP production in mutated cells as well as control 
cells. The amount of cAMP produced in mutated cells versus wild-type would then be 
quantified using enzyme-linked immunosorbent assay (ELISA). After the first round, 
CRISPR failed to produce the desired mutation, the guide RNA was modified, and the 
process repeated three times. Although we successfully created the desired edit in the 
third round, other mutations directly flanking upstream and downstream predicted that 
ADCY5 protein would be non-functional, so the ELISA was not performed. Overall our 
results provide a model of the molecular basis of ADCY5 related-dyskinesia, such that 
high levels of cAMP during early development decreases neuronal cell-type production, 
as well as exerting its downstream effects on D2 (dopamine 2) receptor and tyrosine 
hydroxylase protein expression, thereby disrupting the dopamine pathway. Understanding 
the pathophysiological mechanisms underlying this disease will help differentiate 
ADCY5 related-dyskinesia from other motor disorders, in order for clinicians to make 




individually diagnose mutation type, quantify cAMP production level, and customize 
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ADCY5-related dyskinesia is a rare genetic neurological movement disorder, with 
early onset in childhood (Mencacci et al. 2015). Although this disease is not fatal and 
does not progress with age (Fernandez et al. 2001), the effects are challenging and 
debilitating for patients and their families. The disease phenotype was first described in 
2001, when Dr. Magali Fernandez and colleagues performed a study on 18 related 
individuals (spanning over five generations) diagnosed with “some variation” of benign 
hereditary chorea (BHC). Case workup, including family history, revealed that patients 
did not continue to deteriorate as in Huntington’s disease, and in some cases, there 
seemed to be improvement with age. Patients’ conditions seemed to be worsened by 
anxiety and stress. There were no marked abnormalities in blood chemistries reported, 
cognitive dysfunction, or shortened life span; MRI’s were normal, deep tendon reflexes 
were normal, and muscle strength and tone were all normal. Needle electromyogram 
(EMG) recordings were used to measure patients’ facial muscle electrical activity which 
displayed myokymic electrical discharges. The disease was re-named to Familial 
dyskinesia with Facial Myokymia (FDFM) due to the various dyskinesias and myokymic 
presentation.  FDFM differs from BHC in the way it clinically presents, such that BHC 
often presents with pulmonary and or endocrine defects and FDFM does not. Also, 
BHC’s predominant symptom is chorea, and although FDFM does manifest with the 
neurological-related chorea, it also presents with other multiple abnormal movements, 




episodes, as well as delayed developmental milestones, with early onset in childhood to 
adolescence (Fernandez et al. 2001).  
In order to analyze the genetic basis of this disease, Fernandez et al. 2001 
examined the family pedigree of the five-generation family study and discovered the 
mode of inheritance to be autosomal dominant, with complete penetrance in males and 
females; and some cases revealed male to male transmission. The authors proposed that 
the gene mutation responsible for FDFM was most likely related to an ion channel due to 
some patients’ positive response to propranolol, a beta-adrenergic antagonist, as well as 
acetazolamide, an inhibitor of carbonic anhydrase. They performed linkage analysis on 
fourteen genomic regions containing genes that code for portions of ligand-gated ion 
channels in addition to genes associated with myokymia or chorea, but it was not 
informative (LOD score of 2.7, below the significance level of 3.0). A haplotype analysis 
was constructed from haplotypes of living affected family members. They found that 
many affected individuals did not share the haplotype with their affected siblings, or even 
affected relative. They also demonstrated that FDFM is not an allelic variant of any of the 
candidate genes examined.   
The first exome sequencing of a FDFM affected individual was performed in 
2012 by Che, et al. The disorder was mapped to a region on chromosome 3 that contained 
a missense mutation in the coding sequence for Adenylate Cyclase 5 (ADCY5). Since 
this discovery, a total of 89 patients presenting with symptoms of FDFM have tested 
positive for a mutation in the ADCY5 gene (Table 1). These individuals include related 




to phenotype relationship. (Chen, et al. 2012; Chen, et al. 2014; Carapito et al. 2015; 
Chen, et al. 2015; Douglas et al. 2017; Dy et al. 2015; Menacci et al. 2015; Chang et al. 
2016). According to my most current literature search, there are 17 identified ADCY5 
point mutations associated with diseased individuals (Douglas et al 2017), as well as one 
amino acid deletion mutation, for a total of 18 identified ADCY5 mutations associated 
with the disease (Table 1).  The p.R418W mutation in ADCY5 is carried by the majority 
of ADCY5 patients examined to date and is associated with the more severe phenotypes 
(Chen, D. et al. 2015; Zech et al. 2017 ).  
The ADCY5 gene is 173,250 bp long and contains 21 exons located on the q arm 
of chromosome 3 (reviewed in Shaw 2015).  The coding sequence is 3,786 bp long, 
encoding 1,262 amino acids (National Center for Biotechnology Information [updated 
2018]).  ADCY5 has two identified splice variants that contain the first half of the 
molecule identified by BLAST analysis against EST databases. The first ADCY5 variant 
ends at domain C1a, and the second variant ends at the beginning of C2. This has been 
found similar to the truncated ADCY5 molecule found in cDNA libraries made from 
canine ventricular tissue. Though inactive on their own, it is hypothesized that the 
truncated isoforms may allow for heterodimerization in vivo (Katsushika et al. 1992).   
ADCY5 is one of the 9 transmembrane human adenylate cyclase proteins 
expressed from the adenylate cyclase genes conserved in all mammals.  There is also a 
10th ADCY protein that is soluble, structurally different from the others and is testis 
specific (Chen et al. 2012; reviewed in Dessauer et al. 2017). ADCY5 encodes for a 





receptors (GPCRs). (Ludwig and Seuwen 2002). The ADCY 5 protein is grouped into 
adenylate cyclase category III (reviewed in Dessauer et al. 2017), which is defined due to 
inhibition by Ca2+, PKA, and Gαi subunit and activation by forskolin, isoproterenol, 
PKC, Gαs & Gβγ subunits, and Mn2+ (reviewed in Hurley 1999).  
The enzymatic role of adenylate cyclase is the conversion of adenosine 
triphosphate (ATP) to cyclic adenosine-3’,5’- monophosphate and pyrophosphate. Once 
cAMP is synthesized, it serves as a second messenger within the cell. Cyclic AMP’s most 
prominent role is to phosphorylate cAMP-dependent protein kinase (PKA), which in turn 
can phosphorylate other molecules causing a wide array of downstream signaling cascade 
effects, including inhibition of ADCY5 in circuit (Dunman and Nestler 1999). A common 
role for PKA is the phosphorylation of the transcription factor cAMP response element 
binding protein (CREB). Phosphoactive CREB translocates to the nucleus where it binds 
the DNA sequence known as cAMP response element (CRE) to regulate the expression 
of a variety of genes that include some involved in neural cell function such as BDNF, 
NGF, and PACAP (Dworkin et al. 2009).  
The transmembrane ADCY proteins have two transmembrane domains (TM1 and 
TM2), each comprised of 6 transmembrane helices each and two cytosolic catalytic 
domains (C1 and C2).  The two catalytic domains have an “a” and “b” subunit. C1 is 
connected to TM1 and C2 is connected to TM2. Residues of both C1a and C2 come 
together in a heterodimer to form the active site at one end of the ventral groove 
(Willoughby and Cooper 2007). The active site of this enzyme is lined with hydrophobic 




arginine residue of C1 and the lysine residue of C2 form the charged interactions of the 
catalytic domain. The C1 domain helps to correctly orient the lysine residue in C2, which 
in turn is necessary for the flexibility of the active site. Any mutation that changes the 
specific amino acid residues located within this catalytic site may affect the specificity by 
preventing proper interaction between C1 and C2 (reviewed in Hurley 1999). 
 In humans, ADCY5 is predominantly expressed in the striatum (Matsuoka et al. 
1997; Kim et al. 2006; Menacci et al. 2013). The dorsal striatum includes the caudate 
nucleus and putamen, and the ventral striatum includes the nucleus accumbens olfactory 
tubercles (Figure 1), both dorsal and ventral subsections make up the basal ganglia, 
subcortical structures involved in movement, learning, and memory (reviewed in Money 
and Stanwood 2018). In particular, the nigrostriatal pathway of the basal ganglia has a 
role in controlling voluntary muscle movement. A study demonstrated that ADCY5 
mRNA expression continues to increase in the human striatum during early development, 
from 50 to 500 days post conception, when compared to other regions such as 
hippocampus, frontal cortex, or medulla oblongata (Menacci et al. 2015). This indicates 
that the level of ADCY5 expression is associated with early development, in a temporal-
spatial manner.  
 A study by Matsuoka et al 1997 used neonatal and adult rat brain to research 
mRNA expression of ADCY1, 2, and 5. They found ADCY5 was restricted to striatum, 
nucleus accumbens, and olfactory tubercle. There was low ADCY5 mRNA expression in 
these regions in the neonatal rat brain, then a significant increase in these same regions 




maturation of striatal neurons, while ADCY2 is more distributed throughout the adult rat 
brain and ADCY1 is abundant in the dentate gyrus of the adult rat brain. The results of 
their entire study show that ADCY protein 1, 2, and 5 expression is brain region specific, 
as well as age specific, which they concluded that these specific proteins may have a role, 
“not only in the synaptic transmission, but also in the differentiation and maturation of 
neuronal cells in the developing brain” (Matsuoka et al. 1997).  
ADCY5 expression has also been characterized in other human tissues. In 2002, 
Ludwig and Seuwen performed a study in which ADCY expression profiles were created 
using 16 different tissues from human as well as HEK 293T cells. Using RT-PCR, they 
found ADCY5 expressed in 14 of the 16 different tissue types, with highest expression in 
heart, brain, and testes. In HEK 293T cells, cDNA expression of most adenylate cyclase 
proteins was found, except 4, and 8; and 2 was faintly detectable. A band of moderate 
intensity for ADCY5 was detected at 300bp (as reviewed in Ludwig and Seuwen 2002). 
Later, expression of ADCY proteins 1, 3, 4, 5, 6, 7, and 9 was confirmed in HEK 293T 
cells (Atwood et al. 2011).  
Interestingly, all the mutations identified in ADCY5 patients occur within the 
catalytic domains of the protein (Chen, et al 2015; Chang et al. 2016; Douglas et al. 2017; 
Dy et al 2016).) (Figure 2).  To determine how these mutations might affect biochemical 
function, a significant study performed in 2014 by Ying-Zhang Chen and colleagues at 
the University of Washington concluded that the FDFM phenotype may be due to a gain-
of function effect due to a mutation found in the adenylate cyclase 5 gene.   HEK 293T 




vector + wild-type ADCY5, or GFP vector encoding two mutations identified in ADCY5 
patients: p.R418W, or p.A726T. They then measured subsequent cAMP production in the 
basal state and under pharmacological regulation by the ADCY class III beta adrenergic 
agonists forskolin and isoproterenol, and the ADCY antagonist, propranolol. ADCY5 
protein levels were not affected by the mutations; however, cAMP levels in mutated 
ADCY5 were significantly higher than basal levels but only when stimulated by 
pharmacologics, demonstrating a gain-of-function effect. This suggested increased cAMP 
could be related to disease phenotype in patients carrying these mutations. (Chen, YZ. et 
al. 2014). They performed whole exome sequencing on affected individuals and 
discovered several missense variants within the ADCY5 gene. Of note, one of those 
variants, includes (c.1252C>T, p.R418W), which is of interest for our study. They also 
mapped these mutations to the catalytic domains of ADCY5. 
To date, there is not a solid understanding of the molecular mechanisms by which 
ADCY5 mutations result in the disease phenotypes. However, there is evidence in the 
literature to suggest that neuronal differentiation might be affected. Production of cAMP 
by ADCY5 affects axon elongation, through the P13-Akt-GSK3 pathway. (Puerto, et al. 
2012). Specifically, the three purinergic receptors P2X7, P2Y1, P2Y13, widely expressed 
in neurons and glial cells of the adult brain, contribute to the regulation of ADCY5. The 
metabotropic receptor P2Y1, promotes axonal elongation through activating cAMP 
production in the distal region of axons of hippocampal neurons, exerting its effects on 
downstream effectors that include neurotrophic factors. The P2X7 and P2Y1 receptors 




(Puerto et al. 2012). An extensive study by Dworkin et al. 2009 found that the 
downstream cAMP target, CREB, has an essential role in neurogenesis of the developing 
mouse brain, where it is found to be constitutively active during neural progenitor cell 
differentiation, and only “transiently activated outside the neurogenic regions” (Dworkin 
et. al. 2009). 
Because axonal elongation and neuronal connectivity are so dynamic during 
development, it is important to consider the dysregulating influence that mutated ADCY5 
might contribute during embryonic stem cell differentiation to a neuronal lineage, and 
specific to dopamine-containing neurons (which are involved in motor control) that are 
often implicated in other motor disorders such as Parkinson's disease (reviewed in Girault 
JA, and Greengard  2004; reviewed in Money and Stanwood 2013). ADCY5 knockout 
mice develop a movement disorder, displaying Parkinsonian-like movements.  
Interestingly, their symptoms were worsened by stress (Chen YZ 2012); and stress is a 
known exacerbator of patients with ADCY5-related dyskinesia (Fernandez et al. 2001; 
Chen DH et al 2015; Dy et al. 2016). Looking at the biochemical regulation of ADCY5, 
it is also known that adenylate cyclase activity is “modulated through dopamine 
signaling” (reviewed in Girault JA, and Greengard 2004). Dopamine receptors, with 
excitatory (D1) and inhibitory (D2) subclasses, are responsible for modulating the ion 
channel permeability upon dopamine binding, thereby influencing the neuronal 
membrane potential (Girault, and Greengard 2004). These changes in membrane potential 
may then in turn affect neuron action potentials. Abnormal firing of motor neurons has 




in such motor diseases. D1 and D2 are G-protein-coupled receptors that activate and 
inhibit ADCY5, respectively (Chen DH et al 2015; Puerto et al. 2012; Iwamoto et al. 
2003). Both D1 and D2 are abundant in the striatal regions of the brain, regions that are 
responsible for movement and motor learning (Chen YZ, et al 2012; reviewed in Money 
and Stanwood 2013) 
Of relevance, dopamine-containing neuronal innervation, as well as dopamine 
receptor expression is dynamic during early development and continues long after birth. 
It has been suggested that “This prolonged developmental timeline provides a large 
window of critical periods during which potential disruptors can induce varied effects” 
(reviewed in Money and Stanwood 2013). Because the striatum (enriched with ADCY5), 
receives innervation from dopamine-containing neurons, any disruptors of this pathway 
could be proposed as problematic. In fact, this may be responsible for the broad-spectrum 





It remains unclear how mutations in ADCY5 contribute to the disease phenotypes 
of ADCY5-related dyskinesia at the cellular level. Evidence suggests that mutant forms 
of ADCY5 result in increased intracellular levels of cAMP in HEK cells. However, it is 




production, or degradation, and if these changes affect development, cellular function, or 
both. If increased levels of cAMP in these mutations do affect neuronal differentiation, 
this would create changes in development and/or the connectivity of neurons and may 
account for the differences we see in phenotypes amongst patients with the same 
mutation.  This study sought to address the question of whether cAMP concentration 
affects the differentiation of dopamine-containing neurons and if endogenous cAMP 
levels are affected by endogenous expression of the most common mutation seen in 
patients with ADCY5-associated dyskinesia, p.R418W. To address these questions, the 
following aims were proposed: 
1. Determine if db-cAMP levels affect differentiation of mouse embryonic stem 
cells into dopaminergic neurons. It is unknown if the effects of the ADCY5 
mutations on disease phenotype results from changes in development, cellular 
function, or both. To better explore this question, mouse embryonic stem cells were 
treated with a synthetic, membrane permeable form of cAMP, N6,2'-O-
dibutyryladenosine 3':5'-cyclic monophosphate sodium (db-cAMP) at a range of 
concentrations (0, 350 µM, 700 µM, 1400 µM or 2800 µM), to see if cAMP affects 
differentiation to dopaminergic neurons. 
 
2. Creation of a CRISPR-induced ADCY5 point mutation, c.1252C>T, in HEK 
293T cells. Although overexpression of ADCY5-GFP fusion protein, containing the 
mutation, p.R418W, increases cAMP production in 293T cells, when 




is not clear if cAMP production is affected when ACDY5 is pharmacologically 
activated in cells that express the mutation from the endogenous loci. To test this, we 
created the c.1252C>T (p.R418W) mutation in HEK 293T cells using the 
CRISPR/Cas9 genome editing system. The mutation was made by first designing the 
sgRNA to target the specific sequence of exon 2 in the ADCY5 gene that contains 
the variant nucleotide of interest. Cas9 made the cut just 5’ upstream to the 
protospacer adjacent motif (PAM) sequence. This point mutation was repaired with 
the desired nucleotide (thymine) by providing the cells with a single-stranded 
template oligo of 150 bp long. The mutation was confirmed by PCR amplifications, 
followed by sequencing. The initial goal was to stimulate cAMP production in these 
endogenously mutated cells by pharmacological regulation with the agonist, 
isoproterenol, then quantify the amount of cAMP produced, using an enzyme-linked 
immunosorbent assay (ELISA). However, because other non-silent mutations were 
also created directly upstream and downstream the variant nucleotide, ELISA was 
not performed. Optimization of the CRISPR-induced mutation to reduce or eliminate 
off-target effects is pre-requisite to performing ELISA, so that in the future, these 
genomic editing tools would be useful to the scientists working with the patient 





MATERIALS AND METHODS 
Neuronal Differentiation of Mouse Embryonic Stem Cells 
J1 murine embryonic stem cell culture 
Mouse embryonic cell, J1 cell line, derived from a 129S4/SvJae male blastocyst 
(ATCC® Cat# SCRC1010) (American Type Culture Collection (ATCC®), Manassas, 
VA). mESCs were plated on a MEF layer of 30,000 cells/cm2 of mitomycin C treated p2 
mouse embryonic fibroblasts (MEFs, CytoSpring LLC, Mountain View, CA) at 30,000 
cells/cm2 in culture dishes pre-treated with 0.1% gelatin solution (STEMCELL 
Technologies™ Inc, Vancouver, BC, Canada or EMD Millipore, Temecula, CA). Cells 
were maintained at 37° C in 5% CO2  in mESC culture media (1% of 2.0 mM L-alanyl-L-
glutamine (STEMCELL Technologies™ Inc, Vancouver, BC, Canada), 1% of 1x 
nonessential amino acids (STEMCELL Technologies™ Inc, Vancouver, BC, Canada), 
0.1% of 1000x 2-mercaptoethanol (Sigma- Aldrich®, Louis, MO), 0.1% of ESGRO® 
Mouse Leukemia Inhibitory Factor (LIF) (EMD Millipore, Temecula, CA), 15% of fetal 
bovine serum and 82.8% of DMEM (Life Technologies, Grand Island, NY and ATCC®, 
Manassas, VA). Approximately 72 hours post initial culturing, mESCs were passaged at 






mESCs were harvested at 50% confluency and plated on 0.1% gelatin-coated TC 
dishes for 48 hours. The mESCs were harvested with 0.05% trypsin EDTA and plated in 
suspension culture at 500,000 cells/well in a 6-well ultra-low adherent dish (Sigma- 
Aldrich®, Louis, MO) in 3 mls of differentiation media (15% of ES-Cult ™ fetal bovine 
serum (STEMCELL Technologies™ Inc,Vancouver, BC, Canada), 10 mM of MEM 
Non- Essential Amino acids, 2 mM of L-glutamine (Life Technologies, Grand Island, 
NY), 1 mM of 1-thioglycerol (Sigma- Aldrich®, Louis, MO ) and DMEM media (Life 
Technologies Life Technologies, Grand Island, NY and American Type Culture 
Collection, Manassas, VA).  Cells were incubated for 4 days. Media was changed every 
other day by transferring the media and EB’s from each well to a sterile 15 ml conical 
tube, allowing settling to the bottom of the conical tube for 5 minutes. Spent media was 
removed and replenished with 3 ml of new differentiation media.   
 
Nestin enrichment 
EBs were transferred to 6-well tissue culture plates and incubated for 7 days. 
Cells were fed every other day with ITSFn media prepared in-lab: 1X DMEM-F12 
(Gibco™ Life Technologies, Grand Island, NY), 5 µg/ml insulin (Sigma-Aldrich®, St. 
Louis, MO ), 50 µg/ml apotransferrin (Athens Research, Athens, GA), 30 nM sodium 
selenite (Alfa Aesar, Haverville, MA),  250 ng/ml fibronectin (Sigma-Aldrich®, St. 






 Expansion of nestin positive cells 
On day 7 of enrichment, cells were harvested, triturated into a single-cell 
suspension, and plated on sterile coverslips at 75,000 cells/cm2 for all treatments and 
replicates. Sterile coverslips were prepared by incubating in 15 µg/ml of poly-L ornithine 
(Sigma- Aldrich®, Louis, MO) for 30 minutes at room temperature, rinsing 3 times in 
sterile PBS, followed by incubation in 1 µg/ml laminin (STEMCELL Technologies™ 
Inc, Vancouver, BC, Canada) for 3-5 hours at 37° C. The cells were expanded for 4 days 
of incubation, feeding every other day in N3 media (ITSFn media plus 20 nM 
progesterone, 100 nM putrescine (all from Sigma-Aldrich®, St. Louis, MO), and 1 µg/ml 
laminin (STEMCELL Technologies™ Inc., Vancouver, BC, Canada or EMD Millipore, 
Temecula, CA),  500 ng/ml Shh, 10 ng/ml bFGF, and 100 ng/ml FGF8b (all from 







Dopamine-containing neuronal differentiation 
 Dopaminergic differentiation was initiated by the removal of cytokine bFGF from 
N3 media and the addition of 200 µM ascorbic acid. Cells were fed every other day for 
10 days, and pre-designated wells were treated on feeding days with 0 µM, 700 µM, 1400 
µM, or 2800 µM db-cAMP, N6,2'-O-dibutyryladenosine 3':5'-cyclic monophosphate 
sodium (CAS# 60-92-4) (Sigma- Aldrich®, Louis, MO). 
 
Immunocytochemistry 
On the tenth day of dopaminergic differentiation, cells on coverslips were fixed 
with 4% paraformaldehyde in PBS for 20 minutes at 4° C. Paraformaldehyde was 
discarded, and cells were washed twice with PBS. The cells were then treat with 70% 
ETOH at room temperature for 5 minutes, rinsed once with rinsing buffer (0.25% 
Triton™-X-100 (Sigma- Aldrich®, Louis, MO) in PBS, and treated with blocking 
buffer  blocking buffer (2% goat serum (Thermo Fisher Scientific, Waltham, MA) in  
0.25 %Triton™-X-100 (Sigma- Aldrich®, Louis, MO) in PBS) for 30 minutes at room 
temperature . After blocking, cells were incubated with primary antibody, mouse- anti-
beta-tubulin III (Cat # MAB1195, Lot # HGQ011611) (R&D Systems, Minneapolis, MN) 
for one hour at room temperature, followed by four washes with rinsing buffer for 5 
minutes each. Goat anti-mouse secondary antibody-Texas Red™ (Ref # T862, Lot # 




hour at room temperature in dark conditions, followed by three washes with rinsing 
buffer. All antibodies were diluted in working buffer (1% BSA, 0.1% Triton-X in PBS). 
After the secondary antibody incubation and rinses, cells were incubated in blocking 
buffer for 30 minutes at room temperature. Blocking buffer was removed and the 
additional primary antibody was added: mouse-anti-TH (Cat# AB152, Lot 2861858) 
(R&D Systems, Minneapolis, MN), and incubated for 1 hour at room temperature. 
Coverslips were then rinsed four times in rinsing buffer with 5 minutes for each wash. 
The additional secondary antibody was added: goat anti-mouse Alexa-Fluor™ Plus 488 
(Ref# A3273, Lot # SE250296) (Invitrogen™, by Thermo Fisher Scientific, Waltham, 
MA) and incubated for 1 hour at room temperature, then rinsed three times with rinsing 
buffer, 5 minutes each wash.  Stained cells were mounted on glass slides with 10 µl of 
ProLong® Gold antifade reagents with DAPI (Life Technologies, Grand Island, NY), and 
left to dry at room temperature overnight.  
Images were taken using a Zeiss Axio Observer Z1 Fluorescent Microscope at 
200X total magnification using 350 nm excitation and 450 nm emission filters to 
visualize DAPI, 595 nm excitation and 615 nm emission filters to visualize Texas Red 






Neuronal cell quantification 
         ZEN 2.3 software modules for image analysis and colocalization (Carl Zeiss Inc, 
Thornwood, NY) were used to quantify total cell number, Tuj1 and TH positive cells. 
Four field of view images were taken per replicate of each treatment and the total number 
of cells were summated. The total numbers per replicate were then averaged to generate 
the average number of cells of per treatment. Both Tuj 1 and TH positive cells were then 
divided by the total cell population, represented by the average DAPI nuclei count. Tuj 1 
and TH positive cell percentages out of total cell population were then used to perform a 
one-way ANOVA. In addition, TH positive cells were also divided by the number of 
Tuj1 positive cells to get the percent dopaminergic neuron type out of total number of 
neurons. 
CRISPR Cas9 HEK 293T Genome Editing 
HEK 293T cell culture 
         HEK 293T cells (Lenti-XTM) (Clontech, Mountain View, CA) were cultured in 
90% Dulbecco's Modified Eagle Medium (DMEM, Life Technologies, Grand Island, 
NY) and 10% fetal bovine serum (Life Technologies, Grand Island, NY) and incubated at 
37°C in 5% CO2. HEK 293T cells were plated in 2 ml of fresh growth media/well, at a 
density of 30,000 cells/cm2. Cell number and viability were assessed using trypan blue 
assay, in a 1:10 dilution with a 0.4% Trypan Blue solution (Life Technologies, Grand 
Island, NY). Cells were counted, using 10 µl of cells in Trypan Blue, loaded on both 




magnification. Cells were then passaged at 30,000 cells/cm2. Media was replenished 
when the media color was orange or yellow, indicating increased acidity, from depletion 
of nutrients, and buildup of H protons. The cells were subcultured when they reached  
90 % confluency. 
 
ADCY5 genomic primer design 
 Forward and reverse primers targeting ADCY5, exon II were designed by web 
tool, Primer-BLAST (Ye et al. 2012. accession # NG_033882.1), to amplify a 441 bp 
region that includes the variant nucleotide of interest. Primers flank all of exon 2, that 
includes the variant nucleotide. (Figure 3). ADCY5 Primers (Integrated DNA 
Technologies, Skokie, IL) were tested on genomic DNA extracted from HEK 293T 
cells.  Primer sequences are as follows: 
Forward: 5- AGGACATCAGAGAGCCCGAT -3’ 
Reverse: 5’- GCTGGCAGCCGTAATAAGC -3. 
 
sgRNA and repair template design  
CRISPR protocol (Addgene, Cambridge, MA) (www.addgene.org/crispr/zhang) 
was followed for editing of the 441 bp region of interest. Both single guide RNA’s 
(sgRNA) design were completed by entering desired sequence of exon 2 of human 
ADCY5 (Accession # NG_033882.1) into www.crispir.mit.edu web tool to generate 
guide options with various scores of off targeting effects. Higher scores are inversely 




(5’-GGAGACCTCAGCCGGATAGT GGG-3’ with score of 93 out of 100) (“original” 
sgRNA); and later, for a dual nickase approach, a second sgRNA was added:  5’-
CACCGCCCGAGAGTGCATCCAGGCG-3’, score of 94). The sgRNA-Cas9 vector 
construct was used to target the sequence in ADCY5 exon 2 that contains the variant 
nucleotide, as well as the 5’ protospacer adjacent motif (PAM) sequence, within the 
correct reading frame.  A single-stranded 150 bp repair template (Integrated DNA 
Technologies, Skokie, IL), that spanned between the Cas9 cut site and the variant 
nucleotide, was created for homology directed repair, in order to obtain the missense 
mutation c.1257C>T, as well as a silent mutation in the PAM sequence from CCC to 
CAC, in order to prevent Cas9 from repetitious cutting after editing.   
 
Px459 Bpil digest 
 Digestion of the initial Px459 (PsPCas9(BB)-2A-Puro (PX459) V2.0 vector, and 
later the PX462 (PsPCas9(BB)-2A-Puro (PX459) V2.0) vector was performed according 
to  protocol (Addgene, Cambridge, MA) (www.addgene.org/crispr/zhang).  Each 
digestion included 1 µg of plasmid, 1 µl Fast Digest Bpil (Cat# FD1014) (Thermo 
Scientific, Waltham, MA), 1µl Fast AP (Thermo Scientific, Waltham, MA), 2 µl 10X 
Fast Digest Buffer (Cat# EF0651) (Thermo Scientific, Waltham, MA), 14.5 µl ddH20, and 





Annealing and phosphorylation of forward and reverse sgRNA oligos 
 Addgene protocol (Addgene, Cambridge, MA) 
(www.addgene.org/crispr/zhang)  was followed for annealing, phosphorylation and 
ligation of forward and reverse sgRNA oligos. 2 µl of each forward and reverse sgRNA 
oligo (100 µM) (Integrated DNA Technologies, Skokie, IL) was combined with 2 µl of 
10X T4 Ligation Buffer (Cat# B0202S) (New England Biosciences®, Ipswich, MA), 13 
µl ddH20, and 1 µl T4 Polynucleotide kinase (Cat#M021S) (New England Biosciences®, 
Ipswich, MA).  
Thermal cycle conditions were as follows:  
 37°C for 30 min, 
 95°C for 5 minutes 
 ramp down to 25°C at 5°C/min (0.08° C/sec) 
 
Ligation 
The Addgene protocol for ligation was followed (Addgene, Cambridge, MA) 
(www.addgene.org/crispr/zhang). After amplification, a working dilution of 
annealed/phosphorylated sgRNA oligos was made at 1:200 for ligation. The ligation of 
annealed/phosphorylated oligos to vector included: 2 µl of Bpil-digested Px459 plasmid, 
1 µl annealed/phosphorylated oligos (1:200), 5µl 2x Quick Ligation Buffer™ (Cat# 
B2200S) (New England Biosciences®, Ipswich, MA), 3 µl dH20, and 1 µl T7 DNA Quick 
Ligase™ (Cat# M0318S) (New England Biosciences®, Ipswich, MA). The ligation 





Bacterial transformation  
Transformation of the initial plasmid PX459 V2.0, and later PX462 (Addgene, 
Cambridge, MA) was performed by combining 2 µl ligation product (Px459 + sgRNA 
insert) with 50 µl Max Efficiency DH5α competent cells (Cat # 18258-012) 
(Invitrogen™, Thermo Fisher Scientific, Carlsbad, CA), then incubating on ice for 2 min, 
heat shock for 45 seconds at 42ºC, and back on ice for 1 minute. SOC media (450 µl) was 
added and bacteria were incubated at 37°C for 30 min, shaking at 225 rpm, before plating 




 Confirmation of proper cloning of the insert was confirmed by single colony 
PCR. The growth of colonies on LB-ampicillin plates indicated a likely successful 
bacterial transformation, as the no-transformation control plates produced no growth, and 
the empty-vector transformation control plate had very few colonies, due to background 
re-annealing of plasmid. Individual colonies were selected at random from the 
transformation plate with a sterile toothpick and swished in individual PCR tubes 
containing PCR cocktail.  EconoTaq Plus® 2X PCR Master mix (reagent) and EconoTaq 
Plus® protocol (Cat # 30035-1) (Lucigen®, Palo Alto, CA) were used, along with 
previously designed sgRNA  oligo (Integrated DNA Technologies®, Skokie, IL) as the 
forward primer and a vector-specific reverse primer (Integrated DNA Technologies®, 




bp, which included our sgRNA. Primers were diluted 1:50 and used in the PCR reaction 
with the following thermal cycle conditions:  
95°C x 2 min, for initial denaturation 
95°C x 30 sec 
52.2°C x 1 min 
72°C x 30 sec 
Repeat 30 cycles 





Mini-culture, plasmid mini-prep, and glycerol stocks 
 Colonies that produced PCR products of correct amplicon size (100 bp) were 
chosen for plasmid mini-prep purification to be used in later transfection. First, those 
same colonies were selected again with a sterile toothpick and placed in individual tubes 
containing LB-broth ampicillin (50 µg/ml), and grown overnight at 37º C, shaking at 225 
rpm, according to protocol (Addgene, Cambridge, MA). Approximately 14 hours later, 
half of the broth was used for a plasmid mini-prep, and the other half combined with 
equal volume of sterile glycerol and froze at -80ºC for preservation.  Plasmid mini-prep 
purification was performed according to protocol (Ref # 740499.50) (Macherey-Nagel, 
Inc., Bethlehem, PA): Bacterial cell pellets were lysed and clarified before DNA was 
bound to spin columns, pellets were washed in buffer supplemented in ethanol, spin 
column membranes were dried by centrifugation, and DNA eluted in 50 µl elution buffer. 
Plasmid concentration was determined by NanoDrop 1000 spectrophotometer (Thermo 
Fisher Scientific, Waltham, MA).   
Transfection of HEK 293T cells 
Transient transfection of PX459-sgRNA construct into HEK 293T cells was 
performed using the Lipofectamine 3000® protocol (Ref L3000-008) (Life Technologies, 
Grand Island, NY). Experimental design included 2 replicates of transfected wells, 2 
replicates of empty-vector transfected control wells, and 2 wells of non-transfected HEK 
cells. Cells were transfected when they reached 90% confluency with 250 ng sgRNA-
Px459 construct as well as 1 µg of the 150 bp single-stranded repair template for 




wells, except the non-transfection control wells were transfected with 750 ng of the 
pMAX vector containing a green fluorescent protein and a puromycin resistance gene 
(Cat# D-00069) (Lonza, Basel, Switzerland). GFP expression was confirmed and 
documented 24 hours post-transfection with a Zeiss Axio Observer Z1 Fluorescent 
Microscope at 200X total magnification. (Carl Zeiss Inc., Thornwood, NY). 
 
Puromycin selection 
  Upon visual confirmation of transfection efficiency, cells were treated with 2.5 
ug/ml puromycin added to the media to allow for sgRNA-Px459-transfected colony 
selection. Media was changed daily and puromycin treatment repeated every 24 hrs until 
all non-transfected HEK cells were dead (approximately 67 hrs). HEK cells were treated 
with 0.05% trypsin to harvest wells individually and transferred to 10 cm plates, plated at 
5,000 cells total per plate and cultured until individual colonies were able to be visualized 
by microscopy. 
 
 Single Clone Selection 
 Upon colony formation, the individual transfected clones were passaged without 
trypsin.  Using a P10 micropipette, under a 10X objective, individual clones were 
aspirated and transferred to a well of a 96-well tissue culture plate for culture. Each time 
cells reached 90-100% confluency, individual clones were successively passaged to 24 
well tissue culture plates, then 12-well plates, and finally transferred to 6-well plates 




each clone was cryopreserved in freezing media (50% FBS, 40% DMEM, and 10% 
DMSO) and the other half pelleted and stored frozen at -20°C, until DNA extraction.  
 
293T cell genomic DNA extraction 
Extraction of genomic DNA from transfected HEK293T frozen cell pellets was 
performed according to Qiagen DNeasy blood and tissue kit and protocol (Cat # 69504) 
(Qiagen, Germantown, MD), and quantified by NanoDrop 1000 spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA).   
 
Sequence confirmation of genomic edit 
 Initial confirmation of CRISPR editing was performed by screening genomic 
DNA from sgRNA-transfected HEK clones for correct amplicon size using polymerase 
chain reaction (PCR). EconoTaq Plus® 2X PCR Master mix (Cat # 30035-1) (Lucigen®, 
Palo Alto, CA) was used, with previously designed ADCY5 primers to confirm band 
size, as well as single amplified product present per transfected clone. A non-transfected 
genomic DNA sample was used as a positive control. Clones producing a single correct 
amplicon product size (~440bp), were sent out for sequencing (Sequetech, Mountain 
View, CA).  Forward and reverse genomic ADCY5 primers previously designed and 
confirmed to target the locus of interest were used: 
Forward: 5- AGGACATCAGAGAGCCCGAT -3’ 








Statistical tests were performed using R statistical software 2013. A one-way 
ANOVA was used to analyze all data, and Tukey’s Pairwise comparison was used to 









Table 1: ADCY5 mutations associated with ADCY5-related dyskinesia, including protein 
domain, and case documentation (adapted from Douglas et al. 2017). Mosaic cases within 
families listed. 
Study New cases # of cases genotyped, 





Chen YZ et al. 
2012 
1 Family 10(19) c.2176G>A C1b 
Chen YZ et al. 
2014 
2 Sporadic (1 
mosaic) 
2 c.1252C>T C1a 
Carapito et al. 
2015 
1 Family 2 c.2088 + 1G>A C1b 
Menacci et al. 
2015 
1 Family (1 
mosaic), 
1 Sporadic 




Study New cases # of cases genotyped, 





Chen DH et al. 
2015 
1 Family (1 
mosaic) 
8 Sporadic (3 
mosaic) 




1 Family (1 
mosaic) 









































































Study New cases # of cases genotyped, 





Meijer et al. 
2016 



















Table 2: Display of DAPI count averages per replicate and overall average, and std. dev. 
and std. error within each treatment. Three replicates of each were listed for each treatment 
level, except for 2800 µM, which included two replicates, due to loss of third. 
 Replicate No treatment 700 µM 1400 µM 2800 µM 
 1 3603 2352 6689         6649 
 2 4026 5122 6368 6504 
 3 2939 4758 6756  
Average 3522.66 4077.33 6604.33 6576.50 
Std dev 547.93 1505.22 207.39 102.53 





Table 3: Statistics for average percent Tuj1 neurons/total cell population (DAPI). Std. dev 
and Std. error of percent Tuj1 positive cells within each treatment displayed.  
Treatment 
(TX) 






No Tx 398 3,524.33 11.38 %  4.60 1.32 
700 µM 499.66 4077.33 14.02 %  6.64 1.91 
1400 µM 622.33 6604.33 9.80 % 3.06 0.88 
2800 µM 468 6576.50 7.45 % 3.30 1.16 
 
 
Table 4: One-way ANOVA statistical output. Statistical output of one-way ANOVA of percent 
Tuj1 neurons/total cell population (DAPI), gives a P-value (<0.05), indicating there is a 
*significant difference in mean percent Tuj1 positive cells amongst treatment levels. 
 DF Sum Sq Mean Sq. F-Value P-Value 
Treatment 3 228.9 76.31 3.393 0.027* 
 
 
Table 5: Tukey’s pairwise comparison for 95% confidence interval for percent Tuj1 neurons/total 
cell population (DAPI) , displays the 700 µM treatment-2800 µM pair are the most significantly 
different: adjusted p-value (0.02) indicates a significant difference between the mean of 700 µM 
and 2800 µM treatment levels. 
Pair diff lwr upr P.adj 
700-2800 µM 6.5661 0.7641 12.3680 0.0211* 









Table 6: db-cAMP treatment does not affect percent TH positive cells out of total cell 
population (DAPI).  The average TH positive cells divided by total cell population (DAPI). Std. 
dev, and Std. error within each treatment level displayed.  
Treatment Ave # TH 
Ave # 
DAPI 






No TX 124 3,524.33 3.51 % 1.76854961 0.510536297 
700 µM 191 4077.3333 5.43 % 3.520809237 1.01637008 
1400 µM 228.33333 6604.3333 3.58 % 1.399712453 0.404062181 
2800 µM 181 6576.5 2.89 % 1.190447928 0.420886901 
 
 
Table 7: One-way ANOVA statistical output. P-value for percent TH positive cells out of total 
cell population (DAPI) is not significant (>0.05).  
 DF Sum Sq. Mean Sq. F-value P-value 
Treatment 3 39.43 13.142 2.599 0.0655 
Residuals 40 202.23 5.056   
 
 
Table 8: db-cAMP treatment does not affect percent TH positive cells out of total number 
of neurons (Tuj1). TH positive cells/Tuj1 positive cells. Std. error within treatment levels 
calculated.   
 No Tx 700 µM 1400 µM 2800 µM 







Table 9: One-way ANOVA statistical output. P-value not significant (>0.05). 
  Df Sum Mean sq F-value P-value 
Treatment 3 374.3 124.78 2.109 0.114 





Table 10: Summary of CRISPR-induced point mutation attempts. Each CRISPR 
attempt listed, including what sgRNA and vector used, and edits made to PAM sequence, 
and variant nucleotide. 


















Cas9 cut site. 
2 original Px459 Yes. 6 /10 10/10 wild-type Minimal 
ambiguous 
base-calling. 






1/6 5/6 wild-type 





4 original Px459 No 2/37 with correct 
edit, some wild-type, 







Table 11: Fold-change values (normalized to GAPDH by densitometry) of TH and D2R in 
1400 µM cAMP-treated neurons comparing to neurons with no cAMP.  
Sample Name Fold-change to no treatment 
Cytosolic TH 1.15 
Membrane TH -2.51  
Cytosolic D2  1.73 









Figure 1: Schematic of the protein structure adenylate cyclase transmembrane proteins. 
The mutations identified in individuals with ADCY5 are annotated. Note all mutations are located 







Figure 2: Schematic drawing of a midsagittal cross section of the human brain.  Display of 
the medial location of the striatum, and the nigrostriatal pathway (dopaminergic motor pathway), 
in relation to the meso-cortico-limbic pathway (Brunelin et al. 2013). From the schematic, we see 




Figure 3: The entire exon 2 sequence of human ADCY5 (NG_033882.1). The intron (not 
highlighted) and exon (grey-highlighted) genomic sequences are displayed. The forward genomic 
primer is underlined, and reverse genomic primer is in bold print; primers were used to target the 





Figure 4:  db-cAMP treatment affects dopaminergic differentiation of murine embryonic stem cells. ICC images  
of neurons day 10 of differentiation, displayed per treatment, taken at 200X total magnification. Tuj1: a class  
III beta tubulin neuronal cell marker. Tyrosine Hydroxylase (TH): dopaminergic cell marker.  DAPI: nuclei staining.  
Merge images visually demonstrate an increase in neurons with 700 µM treatment, and then a decrease in overall  





Figure 5: db-cAMP treatment affects the average number of DAPI. Error bars display mea
n +/- SEM. Average number of DAPI stained nuclei/treatment level was generated by the summa
tion of DAPI count within four field of views, and then averaged by the three replicates/treatment 
level. This process was repeated for Tuj1 and TH. The bar graph displays an increasing trend in o








Figure 6: db-cAMP treatment affects percentage of Tuj 1 and TH out of total cell 
population (DAPI). Bar graph of percent average neurons, represented by Tuj1 positive cells, 
divided by the total cell population (DAPI) per treatment. Side by side comparison with percent 
average TH positive cells divided by the total cell population (DAPI), per treatment. Percent Tuj1 
and TH cells display similar trend of dramatic increase with 700 µM treatment, and then a 













Figure 7: One-Way ANOVA statistical output displays db-cAMP treatment has a 
significant effect on percent Tuj1 positive neurons out of the total cell population. A). Box 
plots display the interquartile range of percent Tuj1 positive neurons amongst treatment levels, 
with the median for each treatment level indicated by the black bar. B). Tukey’s pairwise 
comparison graph for 95% confidence interval, displaying the 700 µM treatment-2800 µM pair 














Figure 8: The one-way ANOVA displays db-cAMP treatment does not affect percent TH 
positive neurons out of the total cell population (DAPI. TH positive cells divided by the total 
cell count (DAPI). A). Box plots display the interquartile range of percent TH positive neurons 
amongst treatment levels, with the median for each treatment level indicated by the black bar. B). 
Table of TH/DAPI calculations and statistical output of one-way ANOVA, gives a P-value (0.06), 
indicating there is a borderline significant difference in mean percent TH positive cells amongst 
treatment levels. C). Tukey’s pairwise comparison graph for 95% confidence interval, displaying 








Figure 9: db-cAMP treatment does not significantly affect the percent TH positive cells out 
of total number of neurons (Tuj1 positive cells). Error bars display mean +/- SEM. TH 
positive cells divided by total number of neurons (Tuj1), displays a slight increase in percent TH 
with 700 µM treatment, then a slight decrease with 1400 µM treatment, followed by a slight 














Figure 10: The one-way ANOVA displays db-cAMP treatment does not affect percent TH 
out of total neurons (Tuj1).  A. Box plot of percent TH/Tuj1 displays the interquartile range of 
percent TH positive neurons amongst treatment levels, with the median for each treatment level 
indicated by the black bar. B. Tukey’s pairwise comparison graph for 95% confidence interval, 
















Figure 11: sgRNA design to target region of variant nucleotide, for CRISPR-induced 
c.1252C>T mutation. The entire exon 2 sequence of human ADCY5 (NG_033882.1) (shaded in 
light grey) within its genomic DNA region (non-shaded). A). CRISPR attempt #1 and 2:  PAM 
(shaded dark grey), targeted sgRNA sequence (underlined), and variant nucleotide (capitalized 
and bolded). Cas9 will cut just 5’ to the PAM sequence (CCC). B). CRISPR attempt # 3: dual 
nickase approach, including both original (underlined), and the second sgRNA (underlined) to 
target variant nucleotide (capitalized and bolded). Both PAM sequences highlighted in dark grey. 
C). CRISPR attempt # 4: Used only the second sgRNA (underlined), which targets a PAM 







Figure 12: Successful transfection of sgRNA and GFP into HEK 293T cells, 24 hours post- 
transfection (CRISPR attempt # 4). A and B. replicates of sgRNA/GFP transfected 293T cells, 
displaying GFP expression, indicating good transfection efficiency. C. non-transfected control 
displays absence of GFP expression, as expected. D and E. empty-vector transfection controls, 
GFP expression indicates good transfection efficiency.  F. Non-transfected control replicate 
displays absence of GFP as expected. G. Fluorescent image of a sgRNA and GFP-transfected 
HEK clone (200X total magnification). H. Brightfield image of sgRNA and GFP-transfected 







Figure 13: Treatment with db-cAMP increases D2R’s expression in cytosol and 
membrane of 1400 µM-treated neurons; cAMP affects TH’s expression in the cytosol and 
membrane of 1400 µM-treated neurons. A). 1400 µM cAMP treated neurons express 
approximately 2-fold more D2R in the cytosol and membrane compared to neurons with no 
treatment (NT). mESC is negative control; HEK 293T is positive control. Each lane has 10 µg of 
protein. B). GAPDH blot for normalizing to D2R. C). cAMP treated neurons express 
approximately 1.15-fold more TH in the cytosol and 2.51-fold less in the membrane compared to 
neurons with NT. mESCs and HEK 293T are negative control. D). GAPDH blot was used for 







cAMP Treatment Affects Neuronal Differentiation of  
Mouse Embryonic Stem Cells 
 
Aim I: determine if cAMP levels affect differentiation of murine embryonic  
stem cells into dopamine-containing neurons. 
 
 My first aim was designed to determine if cAMP levels affect differentiation of 
mouse embryonic stem cells into dopaminergic neurons.  My hypothesis was that 
increased cAMP during neuronal differentiation would have some effect on either total 
cell numbers, number of neuronal cell type, morphology of neurons, or all of the above. 
We optimized the dopamine-containing neuronal differentiation protocol published by 
Kwon et al. 2014, to achieve efficient directed differentiation of mESCs into dopamine-
containing neurons, confirmed by the presence of Tuj1 and TH, using 
immunocytochemistry (ICC)  
 
cAMP treatment affects morphology of neurons 
The ICC results demonstrate neuron morphological change with increasing cAMP 
treatment (Figure 4). Looking across the treatments, we see a high concentration of 
bundle of neuronal processes, which appears to be slightly increased with the 700 µM 




as well as a change from bundles of neuronal processes, to semi-sparse collection of 
neurons, with more prominent somata. We see a dramatic change in morphology in the 
2800 µM treated cells, specifically the least dense presentation of neurons, and most 
prominent somata.  
 
cAMP treatment affects the overall cell population 
Through quantification software post ICC, we were able to confirm cell count 
differences amongst db-cAMP treatments and perform statistical analysis on those 
results. The number of cells counted/treatment based on DAPI, display an increasing 
trend from no treatment to 1400 µM db-cAMP, average cell counts increase, followed by 
a decrease in average cells counts with the 2800 µM treatment (Figure 5) (Table 2).  
 
cAMP treatment affects the percent of Tuj1 positive cells in the population 
The effect of db-cAMP on the percent of Tuj1 positive cells (representing putative 
neurons) out of the total cell population also seems to change with dosage of db-cAMP.  
Visualized by ICC, the density of neurons appears to increase with 700 µM treatment 
compared to no treatment. There is a marked continual decrease in neuron density from 
700 µM to 1400 µM and 2800 µM. This threshold effect suggests that at higher cAMP 
treatment, there is a decrease in the overall percentage of cells that differentiate into 
neurons. Cell quantification, followed by statistical analysis of the percentage of Tuj1 
cells, confirm this interpretation.  Box plots display a dramatic increase in the percent of 




the 1400 µM treatment and even lower in 2800 µM treatment. (Figure 6) (Table 3). For 
the  percentage of neurons (Tuj1 positive cells) out of the total numbers of cells (DAPI 
count), the one-way ANOVA (Table 4) showed there  was a significant difference in the 
mean percent amongst treatments (P-value<0.05); specifically, the Tukey’s pairwise 
comparison (Table 5) shows that the mean percent of Tuj1 positive cells in the 700 µM 
treatment is significantly different from the 2800 µM treatment (adjusted P-value=0.021) 
(Figure 4). Although visually and quantitatively we see an increase in percent Tuj1 with 
the 700 µM treatment vs. no treatment, this is not significantly different from the no 
treatment. 
 
db-cAMP treatment does not affect percent TH positive cells out of total cell population 
(DAPI) 
For the percent of TH positive cells (representing dopamine-containing neurons) 
out of the total cell population (DAPI count), we see a similar trend as with percent 
Tuj1/DAPI; there is a dramatic increase in the mean percent of TH positive cells from no 
treatment to 700 µM, then it tapers down in the 1400 µM and 2800 µM (Table 7). 
Because Tuj1/DAPI and TH/DAPI display similar trends, we suspected that cAMP might 
not affect TH positive cells specifically, but overall neuronal differentiation efficiency.  
To confirm this, the percentage of TH positive cells out of the Tuj1 positive cells were 
determined, and results are discussed under the next heading.  A one-way ANOVA was 
performed (Table 7) on percentage of TH-expressing cells out of the total number of 






db-cAMP treatment does not affect the percent of TH positive cells out of total neuronal 
cell type 
 
The percent of Tuj1 cells that are also TH positive represent those neurons who 
have differentiated to produce dopamine (Table 8). The one-way ANOVA for TH/Tuj1 
reveals there is not a significant difference amongst mean percent TH out of total neurons 
(Tuj1) (Table 9).  
 
The Creation of the ADCY5 p.R418W Point Mutation 
in 293T HEK Cells.   
 
 
Aim II: characterize the effect of p.R418W mutation on cAMP levels in HEK cells 
  My second aim sought to characterize the effect of the p.R418W mutation on 
cAMP levels in 293T HEK cells. Our hypothesis, based on previous research by Chen et. 
al. 2014, predicted that this point mutation produces higher levels of cAMP in mutant 
cells, compared to wild-type, when stimulated with the agonists, forskolin and 
isoproterenol. To attempt to characterize endogenous expression levels of cAMP in cells 
with the p.R418W mutation, a CRISPR sgRNA-plasmid construct was designed to 
transfect 293T cells and target the ADCY5 gene, exon II, to create a double stranded 
break just 5’ to the PAM sequence, upstream the variant nucleotide c.1252 (Figure 11). A 




cell’s own homology directed repair mechanism to edit the variant nucleotide to the 
desired mutation: c.1252 C>T CRISPR genome editing of HEK 293T cells was attempted 
a total number of 4 times, each with a slight modification of the previous attempt (Table 
7). 
 
Confirming Transfection Efficiency 
 
 To confirm transfection efficiency of our sgRNA-plasmid construct in all 
attempts, a GFP-plasmid was also transfected simultaneously, then visualized by 
fluorescent microscopy. Each CRISPR attempt produced an average transfection 
efficiency of over ~80 percent. In the final attempt, the presence of green fluorescence in 
transfected cells about an 80-90 percent transfection efficiency (Figure 12).  
 
 
Confirmation of CRISPR Edit 
 
The creation of CRISPR-induced c.1252C>T point mutation in 293T cells was 
attempted a total of four times in order to achieve the correct edit (Table 10).  Our first 
attempt we used the aforementioned sgRNA and PX459 vector, however, due to technical 




few that survived did not contain the edit upon sequencing. All sequences revealed 
ambiguous base-calling, after PAM cut site. One of those clones revealed wild-type at 
variant nucleotide. Two out of three sequences revealed an incorrect PAM edit: CCC to 
CGC, and the other CCC to GCC (Appendix A).  
The second attempt did not include any changes to the sgRNA; however, 
technique optimization of the single colony selection improved survival of clones. More 
clones (32 experimental, and 5 control clones) were harvested and, based on PCR clone 
selection, ten experimental and one control were sequenced. Sequence results of 
experimental clones revealed all sequences were wild-type (Appendix B). However, 
some of the clones contained the silent PAM mutation. The 5’ end of sequences were 
fairly clean, until downstream the Cas9 cut site, where some sequences revealed 
ambiguous base calling, indicating the target site was cut, but repair introduced INDELS 
and other mutations. The control clone revealed wild-type at variant nucleotide and the 
PAM sequence, as expected.  
Because sgRNA-dual-nickase approach has been shown to be more efficient at 
on-target CRISPR genome editing than sgRNA (Gopalappa et al. 2018), the third 
CRISPR attempt included the use of the original sgRNA, and a second sgRNA (“dual 
nickase”) targeting nearer to the variant nucleotide. Both original and dual nickase 
sgRNA were cloned into a new vector (PX462) that contained D10A Cas9 mutation, 
allowing for a single stranded cut from each sgRNA-Cas9 construct. Single colony 
selection was again successful, with 53 experimental clones, and 12 control clones. After 




experimental clones and one control clone were sequenced. Sequence results revealed all 
clones remained wild-type at the variant nucleotide, except for one clone (#10) that 
contained the desired edit on the reverse strand (Appendix C). All sequences contained 
ambiguous base calling between the 5’ PAM and the variant nucleotide. It is also likely 
that a mixed population of transfected HEK cells was obtained during initial single 
colony selection, as this is an inefficient process even though optimization of technique 
improved harvest. The purified PCR product of clone # 10 was later subcloned to 
determine if there were mixed alleles. Sequence results of subcloning revealed sequences 
from a mixed cell population due to more than two alleles. (Appendix D). Only one of the 
six experimental clone sequences contained the correct “CCC” to “CAC” PAM edit, the 
rest did not (Appendix E). The control clone sequence revealed a clean (non-ambiguous 
base calling) sequence with wild-type variant nucleotide and no PAM edit, as expected 
(Appendix F). BLAST analysis on the control sequence revealed 99% homology to wild-
type human ADCY5 exon II.   
The fourth and final CRISPR attempt was optimized based on the observation of 
previous attempt #2, where the PAM edit was made with minimal to no off-targeting 
effects, even though the variant nucleotide was not editing. It seemed likely that the clean 
PAM edit was due to the cut site’s proximity to the repair site, in this case the PAM 
repair was made because the cut site was only two nucleotides upstream. Therefore, for 
the last CRISPR attempt, the second sgRNA that we designed for dual nickase was 
cloned into the original vector (PX459), allowing for a double stranded break in closer 




upstream this time, as opposed to 65 bp upstream as in our second attempt. Single colony 
selection was the most efficient this fourth attempt, with the initial selection of 300 
clones. A total of 43 clones (39 experimental and 4 control) were used to harvest genomic 
DNA. PCR screening was performed on all 39 experimental clones, and 4 control clones 
(two from each replicate of the initial empty-vector transfection controls, and one non-
transfected control). PCR results revealed a high success of single PCR product of correct 
size (Appendix G). Of the 39 experimental clones, 37 were sequenced, along with control 
clones, and one non-transfected control. Sequence chromatograms revealed various edits 
of the variant nucleotide, with some clone sequences that contained a c.1252C>G edit, as 
well as other mutations, there were some that remained wild-type, and some had too 
many ambiguous base-calls to read the sequence accurately (Appendix H). Successfully, 
there were two sequences (#13 and #36) that contained the correct c.1252C>T edit in the 
forward strand (Appendix I). However, these two sequences also contained other non-
silent mutations directly upstream and downstream the variant nucleotide.  None 
contained the PAM edit, as expected because the new cut site is just 5’ to the new PAM 
sequence, which is downstream the original PAM sequence (Appendix J). All control 
clones contained wild-type sequences as expected. BLAST analysis of control clones 









   I have demonstrated through directed differentiation of mouse embryonic stem 
cells that db-cAMP treatment in vitro does in fact affect total cell numbers as well as 
percentage of cells that undergo neuronal differentiation. Based on the average DAPI 
count, our experiments reveal an overall increasing trend of total cell population starting 
from no treatment up 1400 µM and 2800 µM treatment. This suggests that increased 
cAMP during differentiation affects either non-neuronal cell differentiation or survival, 
yet without the dramatic drop in cell count at higher the cAMP treatments, as we see with 
neuronal cell type. This difference in the trend of cell count between non-neuronal and 
neuronal cell types indicates increased cAMP influences general cell numbers, but its 
distinct effect is also cell-type specific.  
Amongst treatment levels of db-cAMP, we also observed an effect on the 
neuronal morphology and number, represented by Tuj1 positive cells, out of the total cell 
population (DAPI count). As reported in the results, ICC visually reveals that with 
increasing db-cAMP concentrations, there is a continual change in neuronal arrangement.  
There seems to be a threshold for producing changes in neuronal presentation, with a 
dense presentation of bundles of neuronal processes in the no treatment and 700 µM, to a 
striking decrease in neuronal density with the higher cAMP treatments (indicated by a 




where not only are neurons the sparsest, but visually, the fluorescent signal of the somata 
become more prominent.  This visual pattern we see is reflected in the quantification of 
neurons (Tuj1 positive cells) out of total cell population amongst treatments; there is an 
initial increase in percent Tuj1 positive cells with 700 µM treatment, then a tapering 
down at the higher cAMP levels. The biological interpretation of the effect that higher 
cAMP has on the neuronal cell population is that during early development, a gain-of-
function mutation in ADCY5 is likely to affect the initial production of neurons, long 
before it may influence differentiation of these neurons to specific neuronal cell type, 
such as dopaminergic.    
Examining the effects of db-cAMP treatment on dopamine-containing 
differentiation, represented by TH positive cells, out of the total cell population (DAPI 
count), we see the same visual pattern on ICC as we do with the Tuj1 cells. The no 
treatment controls display bright, clustered TH positive neurons, with a subtle increase in 
TH signal in the 700 µM merge image, then we start to lose TH signal in the 1400 µM, 
and then only a small amount of distinct TH signal present with 2800 µM, where 
projections are sparse.  Quantitative analysis of TH count divided by DAPI count, 
yielding percent TH positive cells, confirms ICC results, and mimics the percent Tuj1 
positive cells’ pattern: a slight increase in percent with the 700 µM treatment, and then 
tapers down in 1400 µM and continued in 2800 µM db-cAMP.  
 Because the percent TH positive cells out of DAPI count results followed the 
pattern of results obtained for percent Tuj 1 out of DAPI, we suspected that the increase 




neuron count (Tuj1). We addressed this by dividing TH cells by Tuj1 cells, which 
removed DAPI background and allowed for TH to Tuj1 ratio. As reported in the results 
section, the percent TH out of total neuron population (Tuj1) was negligible and not 
statistically significant.  Therefore, we concluded that cAMP does not affect the percent 
dopamine-containing differentiation efficiency, but rather affects neuronal differentiation. 
This information ties back to what was stated earlier in this discussion, that higher levels 
cAMP during early development could affect neuronal cell type, prior to neuron-specific 
differentiation. Specifically, the process of neurogenesis starts with exuberant neural 
progenitor cell production (NPC), followed by migration, differentiation, synaptogenesis, 
selective apoptosis, myelination for select neurons, and finally synaptic pruning. 
However, many neurons remain non-myelinated. (reviewed in Kristiansen M, and Ham J. 
2014).     
Other studies that have included cAMP treatment during cell culture include 
research by Branton et al. 1998, where they demonstrated that treatment with db-cAMP, 
ranging from 500 µM to 1000 µM of a cell suspension made from rat embryonic ventral 
mesencephalon, , showed a dramatic increase of TH positive cell survival at the 700 µM 
level, and then a gradual decrease above 700 µM concentration. This coincides with the 
threshold effect we see in our experiments with cAMP treatment, from an increase in 
neuronal production at lower concentrations, to a decrease in higher levels.  However, 
that study did not include a general neuronal cell marker such as Tuj1. It is likely that the 
pattern that they are describing could be due to an overall increase in general neuron 




they report the addition of survival promoting factors that included 700 µM db-cAMP, 
during in vitro differentiation of mESCs to dopaminergic neurons, produced an increase 
in the percentage of cells, expressing TH mRNA, with an upregulation from 9 percent (on 
day 4) to 76 percent (on day 16). Also, in a genome-wide profiling study of dopaminergic 
differentiation of hESC (Momĉilović et al. 2014), cAMP synthesis was identified as one 
of the upregulated pathways, and they demonstrated that the addition of 200 µM db-
cAMP during in vitro dopaminergic differentiation increased DA neuron yield by 5 %. In 
an earlier study by Michel and Agid, 1996, found that the addition of db-cAMP 
specifically promotes dopaminergic development, but not GABAergic, or serotonergic 
neurons. 
As previously described, the study by Chen et. al 2014 showed that exogenous 
overexpression of ADCY5 p.R418W mutation increased cAMP production, above wild-
type levels, in pharmacologically activated 293T cells, using beta-adrenergic agonists, 
forskolin and isoproterenol. In fact, they demonstrated an almost 10-fold increase in 
cAMP production, compared no treatment cells, as measured by ELISA. Combining this 
key information with our results that demonstrate cAMP treatment affects the overall 
production of neurons and altered neuronal morphology, with the knowledge that 
ADCY5 is expression in the striatum increases dramatically during early development 
(Menacci et al. 2015), it is not surprising that neurogenesis during early development 
could be dramatically altered at any of those stages. It is likely that the decreased 




synaptogenesis, where initial cell density is crucial in determining selective apoptosis 
(Kristiansen and Ham 2014).   
Based on the above information, one could predict that a higher level of cAMP 
during early development could result in the ADCY5 disease phenotype. However, it is 
not known what the actual cAMP concentrations are in ADCY5-related dyskinesia 
patients, or if there are varying cAMP concentrations amongst patients, but this could 
account for the wide spectrum of clinical presentations. 
Other possible effects of increased cAMP levels by mutated ADCY5 may include 
disruption of the other components of dopamine signaling, specifically dopamine 
receptor expression and enzymes responsible for dopamine synthesis. Data derived from 
experiments conducted by Linh Pham (unpublished data 2018) seem to support this 
hypothesis. Linh looked at the effect 1400 µM db-cAMP on the protein expression of 
dopaminergic receptor (D2R) and tyrosine hydroxylase (Figure 13) (Table 11). 
Immunoblot analysis revealed an approximately 2-fold increase of D2R in the cytosol as 
well as in the membrane of the neurons differentiated in the presence of 1400 µM db-
cAMP.  It has been reported that “D1 and D2 receptors express distinct patterns of 
affinity to dopamine and interact differently with one another depending on synaptic 
concentrations of neurotransmitter” (reviewed in Korchounov et al. 2010). In fact, “while 
both D1 and D2 receptors are abundant in the striatum, the expression pattern of D1 and 
D2 receptors in the axon terminals, dendrites, and spines are obviously diff erent by 
electron microscopic analysis” (reviewed in Hisahara and Shimohama 2011). Because the 




production, this provides a theoretical basis to suspect that an increase in D2 postsynaptic 
expression would disrupt the cAMP downstream substrates such as DARPP-32, that 
modulate other neurotransmitters (reviewed in Hisahara and Shimohama 2011).   
 Looking at TH protein expression levels, there was 1.15-fold increase in 
cytosolic TH expression and a 2.5-fold reduction in membrane TH expression in neurons 
differentiated in the presence of 1400 µM db-cAMP when compared to no treatment. As 
a control, the results also reveal no TH expression present in mESCs or HEK 293T cells, 
which supports that TH expression is associated with dopamine-containing neuronal 
differentiation. The change in TH expression coincides with our finding that 1400 µM 
db-cAMP treatment causes an overall decrease in the neuronal cell population.  With 
fewer neurons present, it is not surprising that the immunoblot analysis displayed less TH 
protein in the membrane fraction due to fewer available neurons, not necessarily less TH 
production per neuron.  
Of relevance to this data interpretation is the biochemical regulation of 
dopaminergic signaling. Dopamine neurotransmitter is packaged in vesicles at the 
presynaptic axon terminal, and upon calcium influx, are released into the synaptic cleft. 
Excess dopamine is recycled back to the presynaptic terminal (reviewed in Daubner et al. 
2011).  
Tyrosine hydroxylase is the rate-limiting enzyme in the conversion of tyrosine to 
L-DOPA. Looking at cellular localization of TH expression in vivo, studies have shown 
that TH is primarily expressed in the soma cytosol, but also in the membranes of the 




1975). Within the soma, TH is expressed in the membranes of the Golgi apparatus, the 
endoplasmic reticulum, and is soluble throughout the cytoplasm, but not found in the 
mitochondrial or lysosomal membranes. Within the processes, TH staining revealed 
organized, linear aggregates that were parallel along the length of the plasma membrane 
(reviewed in Pickel et al. 1975).  
The enzymatic activity of tyrosine hydroxylase is inhibited by a dopamine 
feedback loop. TH is phospho-activated by PKA (directly downstream cAMP), and in 
turn, this phosphorylation makes TH less susceptible to the feedback inhibition loop. 
Studies also revealed that TH is associated with regulatory proteins, such as PP2A and 
AADC, forming complexes that aid TH proximity to secretory vesicles, allowing for 
quick availability of dopamine transport to vesicles (reviewed in Daubner et al. 2011).   
The upregulation of the inhibitory D2 receptor coupled with the 2.5-fold decrease 
of TH in the membrane fraction of neurons differentiated in the presence of db-cAMP 
(which includes the endomembrane compartments necessary for dopamine secretion), 
suggests dopamine signaling is compromised in neurons exposed to high levels of cAMP.  
Though there was no significant change of TH expression in the cytosol (1.15-fold), this 
doesn’t necessarily mean this population of enzymes would not be impacted by increases 
in endogenous cAMP, as inhibition of enzymatic activity would not be detected by 
immunoblot. To explore this as a mechanism related to ADCY5-dyskinesia, we would 
have to repeat these experiments and perform TH enzymatic assays with protein extracts 




 These data suggest that an increase in cAMP may not just affect number of 
neurons produced during early development, which not only would affect connectivity, 
but also the amount of available D2R receptors in the cytosol and membrane. The change 
in availability of dopamine receptors, will inevitably affect ion channel permeability upon 
dopamine binding, ultimately affecting neuron firing (Girault JA, and Greengard P. 
2004). The work conducted by Linh Pham (2018) contributes to this project; however, it 
is important to take into the consideration the limitations of those experiments. The 
protocol used to extract membrane proteins, may not have been specific to cell membrane 
fraction, but might also include intracellular organelle membranes. If experiments were 
repeated, it would be important to use a cell membrane specific extraction protocol as 
well as include a cell surface specific marker in immunoblot analysis, and even an 
endomembrane marker to ensure we are not getting significant amounts of organelle 
membrane. Examining the D1 subclass receptor protein expression under cAMP 
conditions would also be beneficial because of its role in increasing membrane potential.  
If increased cAMP during early development affects dopamine inhibitory receptor 
protein expression, then a plausible treatment may include D2 receptor antagonists to 
inhibit overproduction, or D1 receptor agonists as a compensatory treatment option; 
however, this option is limited because cells will often adjust receptor expression in 
response to exogenous drug treatment. In fact, DA excitatory receptor agonists may be an 
optimal choice because “DA receptor agonists exert their pharmacologic eff ect by 
directly activating DA receptors, bypassing the presynaptic synthesis of DA” (reviewed 




When considering treatment for ADCY5 patients, it is important to note that two 
other movement disorders that result from disrupted dopaminergic signaling, Parkinson’s 
(PD) and Huntington’s (HT) diseases differ in their presentation compared to ADCY5-
related dyskinesia (AD) patients. Both PD and HT have a much later onset in adulthood 
than AD patients, which can present with symptoms as early as six months of age 
(Menacci et al. 2015). AD patients do not usually experience cognitive defects, as is 
common with both PD and HT. PD is more associated with bradykinesia and akinesia 
and can display dementia as the disease progresses. Although HT and AD both 
experience dystonia, chorea, and dysarthria, AD patients are mostly affected by 
involuntary movements, whereas HT patients also experience impaired voluntary 
movement (Chen et al. 2015; Mayo Clinic 2018). It has also been reported that a unique 
symptom of AD is myokymia (Menacci et al. 2015), whereas a unique feature of PD is 
tremor (reviewed in Hisahara S, and Himohama 2011). Looking at the cellular level, 
another key difference is that PD has been characterized as a loss of kinesis function due 
to loss of midbrain dopaminergic neurons (reviewed in Hisahara S, and Himohama 
2011). Only about 15 percent of PD patients have been linked to genetic mutations in 
LRRK2, PARK7, PINK1, PRKN, or SNCA, as well as other genes not listed here, but 
most cases are sporadic (NCBI 2012). HT is caused by an autosomal dominant genetic 
mutation in the HTT gene that causes loss of striatal neurons (Mayo Clinic 2018). 
Knowing how AD’s clinical presentation is distinguished from other movement disorders 




cellular/molecular level, unique treatment options and timing of treatment can be 
customized, maximizing patient care.  
The findings of this research allow for collaborators to make informed decisions 
about therapeutic options, specifically narrowing the selection of pharmacologic 
treatments, such as an ADCY5 isoform-specific inhibitor (Chen YZ et al. 2014; reviewed 
in Hurley 1999), or cAMP-specific PDE 4, 7, or 8 agonist (reviewed in Raker 2016) to 
increase degradation of cAMP. These drug treatments can be tested first on patient iPSCs 
for efficiency of elimination of excess cAMP, before going to clinical trials, minimizing 
the unnecessary trial and error on actual patients. These patient iPSCs will be critical in 
narrowing the gap between benchtop to bedside treatment. Individual patient genomic 
DNA can be used to perform exome sequencing to determine mutation-type, followed by 
creation of patient iPSCs, which will allow scientists to perform experiments tailored to 
individual patients, testing highly selected pharmacologics to determine efficacy and 
appropriate dosage.   
 
CRISPR-Induced Point Mutation 
 Our first attempt failed due to inefficient single clone selection, and sequence 
results revealed that our sample was most likely from a mixed population of cells, as 
opposed to monoclonal. In our second attempt, single clone selection was much more 
efficient due to technique optimization, however sequence results all wild-type at variant 




mutations and INDELS created. In the third attempt, a dual nickase approach was used in 
hopes to increase efficient repair sequence results revealed mostly wild-type, with other 
mutations, including INDELS.  
By learning from previous attempts, we optimized the final attempt by designing 
a sgRNA that would target closer to the variant nucleotide, in hopes to increase repair 
efficiency We successfully edited the variant nucleotide of interest in two transfected 
HEK clones out of 37 experimental clones sequenced; we were unsuccessful in making 
that our only edit. In fact, every sequence examined contained non-silent mutations. This 
is not surprising as CRISPR is known for high targeting efficiency but inefficient repair 
(reviewed in Paix et al. 2017; Aird, et al. 2018). In fact, single nucleotide edits have a low 
efficiency of 0.1 percent 5 percent (Komor, et al 2016). In all four attempts, we 
demonstrated that our sgRNA design found its target site and a cut was made, but with 
low repair efficiency.  The fourth attempt was by far the most successful, however still 
needs more optimization to limit off-target mutations. This optimization can be 
accomplished by understanding the full capabilities of CRISPR technology and learning 
from what other scientists have done to optimize their CRISPR experiments.  
 CRISPR made its formal debut in 2012 (Jinek et al. 2012), and since then its use 
and breadth of application has accelerated dramatically in the field of research (reviewed 
in Hsu et al. 2014). Some of the initial obstacles with CRISPR included inefficient 
delivery by plasmid or viral vectors, which in turn can lead to overexpression of the 
vector, producing off-targeting editing (reviewed in Jacobi A 2017). CRISPR initially 




a wider array of Cas9 endonucleases from subtypes I and II, and now with genetically 
engineered Cas nucleases, researchers can use enzymatically inactivated, or “dead” Cas9 
(dCas9), fused with a transcriptional activator or inhibitor to allow for binding of Cas9-
sgRNA complex, without cutting. The tethered dCas9 can therefore be used for gene 
activation or inhibition, or even epigenetic applications (reviewed in Hsu et al. 2014).  
 A common limitation to CRISPR editing is low efficiency of homology directed 
repair (Aird, et al. 2018). Because the enzymatic activity of CRISPR endonucleases can 
stimulate the host cell’s NHEJ as well as HDR, this increases likelihood of getting 
nucleotide insertions and deletions, known as INDELS (reviewed in Hsu et al. 2014). 
From my own observations using CRISPR, it also seems likely to get off target editing, 
including INDELS and point mutations, based on how close the edit site is to the cut site. 
As seen in our initial attempts, the further downstream the edit site is to the initial cut 
site, the more likely of getting other editing events such as point mutations and INDELS. 
Our final CRISPR experimental design included a cut site that had greater proximity to 
the repair site, much closer than previous sgRNA-transfection attempts. This indeed 
improved our editing efficiency, as it was the only time we achieved the correct edit of 
the variant nucleotide, but still it created other off target, non-silent mutations. It is also 
probably that once edited, using the repair template, there are still mutations naturally 
occurring within the HEK 293T genome, not induced by the sgRNA transfection. Other 
researchers using CRISPR have circumvented the low repair efficiency by optimizing 
CRISPR design as well, using novel techniques. A recent study by Aird, et al. 2018 used 




sgRNA ribonucleoprotein complex (non-vector delivery), to ensure presence of repair 
template in proximity to cut site.  As reviewed in other literature, this approach has been 
shown to decrease the risk of an immune response from the host cell, increases the 
stability of the Cas nuclease, and limits the Cas9 components: allowing quick termination 
of cutting once the edit has been made. This thereby limits the off-targeting effects 
compared to vector delivery (reviewed in Jacobi A 2017). Referencing back to the Aird, 
et al 2018 study, their results demonstrated increased efficiency in different target loci of 
multiple cell types, with a 5 to 11-fold increase in HDR efficiency. They also confirmed 
efficiency at the gene expression level, using qPCR, and found a 2-fold increase in HDR 
efficiency using the tethered repair oligo method, compared to untethered Cas9. 
Another approach that may improve precise editing is base editing, a modified 
CRISPR technique to create a point mutation within the genome without creating a 
double-stranded break, and conversion is deemed irreversible. (Komor et al. 2016). Base 
editing makes use of dCas9, fused to a cytidine deaminase enzyme, allowing for direct 
conversion of cytidine to uridine (essentially a C to T, or G to A transition mutations). 
This conversion can take place within five nucleotides of target binding. Research at the 
University of Harvard, Liu lab, has successfully demonstrated this base editing using four 
human and murine cell lines, with “permanent correction of approximately 15 percent to 
75 percent of total cellular DNA with minimal (typically ≤1 percent) INDEL formation” 
(Komor et al. 2016).  
Moving forward with the CRISPR portion of this project, future work could 




primers for initial PCR confirmation of edit, for more specificity. 3). A base editing 
approach could be tried as an alternative to traditional CRISPR. Once a monoclonal cell 
line with the desired edit has been created, it would critical to then perform and optimize 
ELISA to quantify cAMP levels produced under mutant conditions compared to wild-
type. Repeating this experiment in multiple cell lines would also be beneficial. This data 
could then be compared to not only the gain-of-function experiments first conducted by 
Chen et al. 2014, but also to compare with the levels of cAMP that produced changes in 
our neuronal differentiation experiment. If these cAMP levels were found comparable to 
the changes we saw in our neuronal differentiation experiments, this would support the 
hypothesis that the p.R418W mutation is likely a gain-of-function mutation, and a more 
definitive biological conclusion could be made about the effects of increased cAMP on 







The data analyzed from our neuronal differentiation experiments provide a base 
model for understanding the pathophysiological mechanisms underlying the ADCY5-
related dyskinesia phenotype. We demonstrated that cAMP levels above 700 µM do not 
significantly affect dopamine-containing neuronal specific differentiation, however it 
does significantly decrease overall neuronal cell type production, as well as change 
neuronal morphology. Our data supports a model where the molecular basis of ADCY5-
related dyskinesia precipitates its effects during early development by altering the 
morphological structure of neuron fascicles and decreasing overall neuron production, 
before differentiation of those neurons take place, and thereby ultimately affecting 
neuronal connectivity and proper signaling. Based on Linh Pham’s data, we also propose 
that downstream effects of high levels of cAMP include increased D2 protein expression 
levels, and decreased levels of the dopamine-synthesizing enzyme, tyrosine hydroxylase, 
within the membrane of neuronal processes, ultimately disrupting the balance of the 
striatonigral dopamine pathway.  
Building upon our model, further investigation will require looking at other 
downstream effects of high levels of cAMP, such as excitatory D1 subtype receptors, 
regulation of CREB, and neurotrophic factors, NGF, PACAP, BDNF, and DARRP-32. 
Our findings are significant when we consider the spatiotemporal gradient of neuronal 
development, and ADCY5 expression. Because the striatonigral dopaminergic pathway 




long after birth into adulthood, the expansive time frame for deleterious effects of 
mutated ADCY5, enriched in the striatum, provides probable cause for the broad 
spectrum of clinical presentation of ADCY5-related dyskinesia.  
 Unfortunately we are not able to compare the levels of db-cAMP that affect 
neuronal differentiation to levels of endogenous cAMP in cells containing the p.R418W 
mutation. Although not completed according to our initial aims, the CRISPR portion of 
this research will still provide a starting point for future optimization of a CRISPR-based 
assay that will be useful to our collaborators in understanding the cellular effects of not 
only the p.R418W mutation; it will also allow for a directed plan for analysis of the other 
17 point mutations known to date. The results of these assays, specifically the quantified 
cAMP under each mutation type, can then be used as a baseline to compare to ADCY5-
related dyskinesia patient samples. Patient samples will allow for their iPSCs to be used 
to perform ELISA to quantify individual levels of cAMP, comparing them to non-
affected individuals as well as other patients with the same mutation, and patients with 
other ADCY5 mutations, ultimately expanding the database of knowledge about the 
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Appendix A: CRISPR attempt # 1 revealed mixed sequence results and no c.1252C>T edit 
made.  A. Chromatogram of clone 2B reveals wrong PAM edit (from CCC to GCC). B. 
Chromatogram of clone 2B reveals ambiguous base calling for most of sequence, but detectable 
wild-type at variant nucleotide (blue highlight).  
 









Appendix B: CRISPR attempt # 2 revealed no edit made to variant nucleotide. Example of 
partial chromatogram of sequence results from CRISPR attempt #2. A). Clone # 1 sequence 
revealed wild-type at variant nucleotide (blue highlight). B). Clone # 1 also contained wild-type 
PAM sequence (blue highlight). C). Clone # 2 revealed a c.1252C>G edit (blue highlight). D). 
Clone # 6 revealed correct PAM edit from CCC to CAC (blue highlight). E). Empty-vector 
transfected control clone revealed wild-type at variant nucleotide (blue highlight). F). Empty-
































Appendix C: CRISPR attempt # 3 sequence results revealed mixed edits made. Example of 
partial chromatogram of sequence results from CRISPR attempt #3. A). Chromatogram of clone # 
4 forward sequence revealed wild-type (blue highlighted C). B).  Chromatogram of clone # 10 
forward sequence revealed c.1252C>A edit (blue highlight), and the reverse sequence reveals 
c.1252G>T edit (blue highlight). C). BLAST analysis of wild-type sequence (query) vs. forward 
and reverse strand of clone 10 sequence (subject) revealed clone 10 sequence is 98% identical to 


























Appendix D: CRISPR attempt # 3. subcloning of transfected HEK clone #10 reveals mixed 
alleles A). Forward and Reverse sequence of one subcloned colony reveals a c.1252C>G and 
c.1252 G>C edit, respectively (blue highlight). B). Forward and Reverse sequence of a second 
subcloned colony reveals wild-type at variant nucleotide (blue-highlight).  
 


















Appendix E: CRISPR attempt # 3 results reveal only one sequence contained correct PAM 
edit. A). Clone # 4 reveals no edit made to PAM (blue highlight). B). Clone # 44 contains the 












Appendix F: CRISPR attempt # 3. Sequence results of empty- vector-control clone reveal 
wild-type sequence. A). Control clone # 44 sequence results revealed wild-type sequence at 
PAM (blue highlight). B). Control clone # 44 sequence also revealed wild-type at variant 
nucleotide (blue highlight), as expected.  
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Appendix G: CRISPR attempt # 4 individual clone PCR confirms correct amplicon size. A). 
Gel # 1, labeled with clone #’s. L= O’Gene mix ladder. Top row reveals a single amplicon of 
correct size (441 bp) for most clones, except clone # 5 and # 11.  B). Gel # 2 reveals all clones 
have single amplicon of correct size (441 bp). E=empty lane, C= no DNA control 










Appendix H: CRISPR attempt # 4 sequence results reveal mixed edits. A). Chromatogram of 
clone # 33 forward sequence reveals incorrect c.1252C>G edit. B). Chromatogram of clone # 29 
forward sequence reveals wild-type at variant nucleotide. C).  Chromatogram of clone #26 

















Appendix I: CRISPR attempt # 4 sequence results reveal 2 clones with edit c.1252C>T 
made. A). Clone # 13 sequence, with c.1252C>T edit (blue highlighted T). B). Clone # 36 
sequence with c.1252C>T edit (blue highlighted T). C). BLAST of wild-type (query) vs. clone 13 
forward sequence (subject) reveals only 89% identical. D). BLAST of wild-type (query) vs. clone 




















Appendix J: CRISPR attempt # 4. Sequence results reveal PAM edit was not made in any 
clone sequences. A). Chromatogram of clone # 13 reveals wild-type at PAM sequence (blue 












Appendix K: CRISPR attempt # 4 sequence results reveal control clone is wild-type. A). 
Empty-vector transfection control clone # 53 (replicate 1) reveals wild-type sequence. B). Empty-
vector transfection control clone # 55 (replicate 2) reveals wild-type sequence. C). Non-
transfected control HEK cells reveal wild-type sequence. D). BLAST analysis of wild-type 
(query) vs. clone #53 (subject) reveals 99% identical sequence. E). BLAST analysis of wild-type 
(query) vs. clone #55 (subject) reveals 99% identical sequence. F). BLAST analysis of wild-type 
(query) vs. non-transfected HEK cells (subject) reveals 99% identical sequence.  
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